Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) is a clinical stage biotechnology company in immuno-oncology, and the news flow around SNSE reflects its focus on cancer drug development, clinical data, and corporate strategy. The company regularly issues press releases on quarterly financial results, clinical trial milestones, capital markets actions, and strategic decisions, which are then furnished to the SEC on Form 8-K.
Recent news has centered on solnerstotug, Sensei’s lead product candidate. The company has released updates from a multi-center Phase 1/2 trial evaluating solnerstotug, a conditionally active antibody targeting the VISTA checkpoint, as monotherapy and in combination with Libtayo® (cemiplimab) in patients with advanced solid tumors. These announcements have highlighted emerging clinical signals in PD-(L)1 resistant “hot” tumors, durability of progression-free survival, safety and tolerability data, and presentations at major scientific meetings such as the ESMO Congress.
Investors following SNSE news also see corporate and financial updates, including quarterly earnings releases, commentary on research and development and general and administrative expenses, and disclosures about cash, cash equivalents, and marketable securities. Sensei has additionally reported participation in investor and scientific conferences, such as healthcare and oncology events where company representatives discuss its tumor microenvironment–focused approach.
A key development in the company’s news stream is the strategic review announced on October 30, 2025, when Sensei’s Board decided to discontinue development of solnerstotug and explore strategic alternatives that may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. Subsequent news has described workforce reductions and the company’s intention to retain a smaller team to manage this process and maintain regulatory and financial reporting compliance.
This news page allows readers to track these evolving themes: clinical data releases, financial results, Nasdaq listing and reverse stock split actions, and updates on the strategic alternatives process, all of which shape the ongoing story of SNSE.
Sensei Biotherapeutics (NASDAQ: SNSE) has appointed William Ringo as chair of its Board of Directors, enhancing leadership during a pivotal phase for the company. Ringo, with over 40 years in the pharmaceutical and biotech industries, brings extensive experience from Pfizer and Eli Lilly. His leadership is expected to support Sensei's objectives in developing innovative cancer therapies, particularly through its unique TMAb™ and ImmunoPhage™ platforms. The company is focused on advancing treatments such as SNS-101 and SNS-401-NG.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Company leaders, including John Celebi and Erin Colgan, will present virtually on March 15 at 10:40 am ET. A replay of the presentation will be available for 90 days on their website. Sensei Biotherapeutics focuses on developing next-generation cancer immunotherapies, utilizing its innovative TMAb and ImmunoPhage platforms for personalized treatment options.
BOSTON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in Citi's 2022 Immuno-Oncology Summit. Dr. Robert Pierce, Chief R&D Officer, will engage in a fireside chat on February 16, 2022, at 2:30 PM ET. The event will be webcast live, with a replay available for 90 days on the company's website. Sensei Biotherapeutics specializes in next-generation immunotherapies for cancer, utilizing its TMAb™ platform for antibody development and ImmunoPhage™ platform to create personalized treatments for various cancers.
Sensei Biotherapeutics has announced key promotions within its leadership team, appointing Erin Colgan as Chief Financial Officer and Robert Pierce, M.D. as Chief Research & Development Officer. Colgan, previously Senior VP of Finance, brings extensive experience from Intarcia Therapeutics and Vertex Pharmaceuticals. Dr. Pierce, who has over 20 years in scientific leadership, shifted from Chief Scientific Officer, enhancing his role to include drug discovery and clinical development. CEO John Celebi expressed confidence in their capabilities to drive the company’s future growth.
Summary not available.
Sensei Biotherapeutics (NASDAQ: SNSE) announced its inclusion in the NASDAQ Biotechnology Index, effective December 20, 2021. This index encompasses biotechnology and pharmaceutical companies meeting specific eligibility criteria, including trading volume and market capitalization. This recognition highlights Sensei's position in the biotechnology sector as it pursues next-generation cancer therapeutics through its innovative TMAb™ and ImmunoPhage™ platforms. The company is advancing its product pipeline, including the antibody SNS-101 and ImmunoPhage cocktail SNS-401-NG for treating cancer.
Sensei Biotherapeutics (NASDAQ: SNSE) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. CEO John Celebi and SVP Erin Colgan will engage in a pre-recorded fireside chat, available for streaming starting November 22, 2021, at 10:00 AM ET on the company’s website. This event highlights Sensei’s innovative immunotherapy approaches, including its TMAb™ and ImmunoPhage™ platforms, focusing on cancer treatments like SNS-101 and the preclinical SNS-401-NG targeting Merkel Cell Carcinoma.
Sensei Biotherapeutics (NASDAQ: SNSE) announced promising preclinical data for its anti-VISTA product candidate, SNS-101. This monoclonal antibody selectively binds to the active form of VISTA in low pH tumor environments, enhancing immune response. Key findings include SNS-101's high affinity and selectivity (~600-fold) for low pH conditions and improved anti-tumor activity when combined with anti-PD-1 therapy. The company is actively pursuing IND-enabling studies and will present findings at the SITC 2021 meeting. A virtual symposium on VISTA's potential will occur on November 16.
SNS-101, a novel tumor-selective anti-VISTA antibody candidate, has been identified by Sensei Biotherapeutics, aimed at overcoming resistance to cancer therapies. Its preclinical data will be presented at the Society for Immunotherapy of Cancer’s annual meeting. As of September 30, 2021, the company reported $156.7 million in cash, ensuring its operational runway through the first half of 2024. R&D expenses increased to $6.4 million, while net loss widened to $9.7 million compared to $5.4 million in Q3 2020. Sensei is progressing with its TMAb platform and anticipates further updates on the ImmunoPhage platform.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Berenberg virtual U.S. CEO Conference on November 9, 2021, at 10:00 a.m. EST. The event will be accessible via a live audio webcast on the company’s website, with a replay available for 90 days afterward. Sensei focuses on developing next-generation immunotherapies for cancer, leveraging its unique TMAb™ and ImmunoPhage™ platforms, including the therapeutic candidate SNS-101 targeting immune checkpoint VISTA and the ImmunoPhage cocktail SNS-401-NG for Merkel Cell Carcinoma.